Payment overview · 2025
General Payments
$233.25
6 reported records · 5 companies
Healthcare provider profile · identity verified
Marcel Rozario, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care · MEDINA, NY · NPI 1992996912
Verified facts
What the public records show
CMS Open Payments records show Marcel Rozario, NP received $233.25 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 66.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $154.03 | 66.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.72 | 10.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.97 | 9.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.14 | 7.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.39 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $233.25 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $154.03 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.04 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 86 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 639 | 306 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 391 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 148 |
| Lisinopril | Lisinopril | 363 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 169 |
| Metoprolol Succinate | Metoprolol Succinate | 322 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 276 | 116 |
| Omeprazole | Omeprazole | 241 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 209 | 86 |
| Furosemide | Furosemide | 206 | 78 |
| Gabapentin | Gabapentin | 193 | 76 |
| Metformin Hcl | Metformin Hcl | 191 | 90 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 174 | 61 |
| Jardiance | Empagliflozin | 172 | 57 |
| Losartan Potassium | Losartan Potassium | 161 | 82 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 45 |
| Eliquis | Apixaban | 133 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 130 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 127 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 63 |
| Sertraline Hcl | Sertraline Hcl | 124 | 50 |
| Ezetimibe | Ezetimibe | 122 | 43 |
| Metformin Hcl Er | Metformin Hcl | 119 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 119 | 41 |
| Prednisone | Prednisone | 119 | 94 |
| Allopurinol | Allopurinol | 118 | 52 |
| Atenolol | Atenolol | 115 | 36 |
| Celecoxib | Celecoxib | 105 | 36 |
| Azithromycin | Azithromycin | 89 | 73 |
| Farxiga | Dapagliflozin Propanediol | 86 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 39 |
| Buspirone Hcl | Buspirone Hcl | 80 | 24 |
| Chlorthalidone | Chlorthalidone | 80 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 34 |
| Trazodone Hcl | Trazodone Hcl | 76 | 32 |
| Alendronate Sodium | Alendronate Sodium | 75 | 28 |
| Ibuprofen | Ibuprofen | 68 | 29 |
| Famotidine | Famotidine | 66 | 32 |
| Alprazolam | Alprazolam | 64 | 29 |
| Simvastatin | Simvastatin | 64 | 35 |
| Glipizide Er | Glipizide | 62 | 27 |
| Montelukast Sodium | Montelukast Sodium | 62 | 23 |
| Xarelto | Rivaroxaban | 61 | 18 |
| Carvedilol | Carvedilol | 59 | 22 |
| Tramadol Hcl | Tramadol Hcl | 57 | 31 |
| Trulicity | Dulaglutide | 56 | 17 |
| Mounjaro | Tirzepatide | 55 | 14 |
| Ozempic | Semaglutide | 54 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 52 |
| Glipizide | Glipizide | 53 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 23 |
| Rybelsus | Semaglutide | 51 | 14 |
| Kerendia | Finerenone | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 15 |
| Spironolactone | Spironolactone | 49 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 18 |
| Ramipril | Ramipril | 47 | 18 |
| Meloxicam | Meloxicam | 45 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 16 |
| Finasteride | Finasteride | 44 | 16 |
| Potassium Chloride | Potassium Chloride | 43 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | 23 |
| Pregabalin | Pregabalin | 42 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | 14 |
| Clonazepam | Clonazepam | 37 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 14 |
| Baclofen | Baclofen | 35 | suppressed |
| Colchicine | Colchicine | 35 | 16 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Lactulose | Lactulose | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | 15 |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 13 |
| Torsemide | Torsemide | 30 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 30 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Diazepam | Diazepam | 28 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 13 |
| Lorazepam | Lorazepam | 28 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 21 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 17 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $233.25 · 6 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, Kerendia, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error